Banner News

Singapore, April 21, 2023 – Update on Detection of the Influenza A subtypes


Credo Diagnostics Biomedical Pte. Ltd. is committed to the post-market monitoring of the reliability of our assays. We have performed nucleotide analysis using the BLASTn method, comparing primers and probes of the assays involving Influenza A virus detection to the sequences of Influenza A H3N8 subtype listed in GISAID, NCBI, and BV-BRC.


Our analysis has confirmed that our assays maintain their stated level of performance.

*The Influenza A virus detection assays include:
. VitaPCR™ Influenza/SARS-CoV-2 (Flu/SC2) Assay (PCRAE0128)
. VitaPCR™ Flu/RSV Assay (PCRAE0106)
. VitaPCR™ Flu A&B Assay (PCRAE0103)


For more information, contact us at


About Credo Diagnostics Biomedical Pte. Ltd.

Credo Diagnostics develops and manufactures innovative, easy-to-use, and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas of Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.


We at Credo Diagnostics pioneer accessible diagnostic platforms to improve the lives of those we love. We believe providing the right information to the right people at the right time leads to better outcomes.